Rubric Capital Amends Mereo BioPharma Stake

TL;DR

Rubric Capital just updated its Mereo BioPharma filing - ownership change incoming.

AI Summary

Rubric Capital Management LP, on April 15, 2024, filed an amendment (No. 14) to its Schedule 13D regarding Mereo BioPharma Group plc. The filing indicates a change in beneficial ownership of the company's ordinary shares, though specific new ownership percentages or dollar amounts are not detailed in this excerpt.

Why It Matters

This filing signals a potential shift in control or influence over Mereo BioPharma Group plc by a significant shareholder, which could impact the company's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Schedule 13D filings often precede significant corporate actions or shifts in shareholder power, introducing uncertainty.

Key Players & Entities

• Rubric Capital Management LP (company) — Filing entity
• Mereo BioPharma Group plc (company) — Subject company
• Brian Kleinhaus (person) — Contact person for Rubric Capital Management LP

FAQ

Filing Documents

• tm2411953d1_sc13da.htm (SC 13D/A) — 42KB
• 0001104659-24-047715.txt ( ) — 44KB

of the Schedule 13D is hereby amended by adding the following

Item 4 of the Schedule 13D is hereby amended by adding the following. On April 15, 2024, Rubric Capital entered into a letter agreement with the Issuer (the “Extension Letter”) in connection with that certain cooperation agreement, dated October 28, 2022 (the “Cooperation Agreement”), between the Issuer and Rubric Capital. Pursuant to the Extension Letter, the parties (i) irrevocably waived the requirement under Section 1(f) of the Cooperation Agreement for Mr. Justin Roberts to offer to resign from the Issuer’s Board of Directors and all applicable committees thereof upon the termination date of the Cooperation Agreement, which was initially scheduled to be immediately following the conclusion of the Issuer’s 2024 annual shareholder meeting, and (ii) extended the termination date of the Cooperation Agreement until immediately following the conclusion of the Issuer’s 2025 annual shareholder meeting. The foregoing description of the Extension Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Extension Letter, a copy of which is attached as Exhibit 99.1 hereto and is incorporated herein in its entirety by reference. Item 7. LIST OF EXHIBITS

of the Schedule 13D is hereby amended by adding the following

Item 7 of the Schedule 13D is hereby amended by adding the following: Exhibit 99.1: Extension Letter, dated April 15, 2024, by and between Rubric Capital and the Issuer (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by the Issuer with the Securities and Exchange Commission on April 15, 2024 ). CUSIP No. 589492107 SCHEDULE 13D Page 5 of 5 Pages

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: April 16, 2024 RUBRIC CAPITAL MANAGEMENT LP By: /s/ Michael Nachmani Name: Michael Nachmani Title: Chief Operating Officer /s/ David Rosen DAVID ROSEN

View Full Filing

View this SC 13D/A filing on SEC EDGAR